Second-generation vaccines against leishmaniasis

Trends in Parasitology

Volumn 21, Issue 5, 2005, Pages 244-249

  Coler, Rhea N ^a,b   Reed, Steven G ^a,b  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b TheraVax   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOLOGICAL ADJUVANT; LEISH 111F; LEISHMANIA VACCINE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; LEISHMANIA; LEISHMANIASIS; NONHUMAN; REVIEW; VACCINATION;

EID: 17444429293     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2005.03.006     Document Type: Review

References (61)

1. S.L. Reiner, and R.M. Locksley The regulation of immunity to Leishmania major Annu. Rev. Immunol. 13 1995 151 177
2. V. Pintado, and R. Lopez-Velez HIV-associated visceral leishmaniasis Clin. Microbiol. Infect. 7 2001 291 300
3. Y. Belkaid CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity Nature 420 2002 502 507
4. K. Kemp Cytokine-producing T cell subsets in human leishmaniasis Arch. Immunol. Ther. Exp. (Warsz.) 48 2000 173 176
5. A. Kharazmi T-cell response in human leishmaniasis Immunol. Lett. 65 1999 105 108
6. H.W. Ghalib Interleukin 10 production correlates with pathology in human Leishmania donovani infections J. Clin. Invest. 92 1993 324 329
7. I. Becker Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2 Mol. Biochem. Parasitol. 130 2003 65 74
8. M.M. Borges Potent Stimulation of the Innate Immune System by a Leishmania brasiliensis Recombinant Protein Infect. Immun. 69 2001 5270 5277
9. T.R. Hawn Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway Microbes Infect. 4 2002 763 771
10. E. Handman Leishmaniasis: current status of vaccine development Clin. Microbiol. Rev. 14 2001 229 243
11. C.L. Greenblatt The present and future of vaccination for cutaneous leishmaniasis Prog. Clin. Biol. Res. 47 1980 259 285
12. F. Modabber First generation leishmaniasis vaccines in clinical development:Moving, but what next? Current Opinion in Anti-infective Investigational Drugs 2 2000 35 39
13. F. Modabber Vaccines against leishmaniasis Ann. Trop. Med. Parasitol. 89 Suppl 1 1995 83 88
14. A. Nadim Effectiveness of leishmanization in the control of cutaneous leishmaniasis Bull. Soc. Pathol. Exot. Filiales 76 1983 377 383
15. E.A. Khalil Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan Lancet 356 2000 1565 1569
16. P.M. De Luca Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis Vaccine 17 1999 1179 1185
17. O. Genaro Vaccine for prophylaxis and immunotherapy, Brazil Clin. Dermatol. 14 1996 503 512
18. W. Mayrink Further trials of a vaccine against American cutaneous leishmaniasis Trans. R. Soc. Trop. Med. Hyg. 80 1986 1001
19. I. Sharifi Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran Lancet 351 1998 1540 1543
20. S.G. Reed, and A. Campos-Neto Vaccines for parasitic and bacterial diseases Curr. Opin. Immunol. 15 2003 456 460
21. E. Handman Passive transfer of Leishmania lipopolysaccharide confers parasite survival in macrophages J. Immunol. 137 1986 3608 3613
22. P.C. Melby Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library Infect. Immun. 68 2000 5595 5602
23. J.M. Burns Jr Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis Proc. Natl. Acad. Sci. U. S. A. 90 1993 775 779
24. S. Rafati Identification of Leishmania major cysteine proteinases as targets of the immune response in humans Mol. Biochem. Parasitol. 113 2001 35 43
25. S.G. Reed Identification of specific and cross-reactive antigens of Leishmania donovani chagasi by human infection sera J. Immunol. 138 1987 1596 1601
26. Y.A. Skeiky Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans Infect. Immun. 63 1995 4105 4114
27. Y.A. Skeiky A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12 J. Exp. Med. 181 1995 1527 1537
28. Y.A. Skeiky LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile J. Immunol. 161 1998 6171 6179
29. J.R. Webb Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis J. Immunol. 157 1996 5034 5041
30. J.R. Webb Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major Mol. Biochem. Parasitol. 89 1997 179 193
31. N.D. Connell Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63 Proc. Natl. Acad. Sci. U. S. A. 90 1993 11473 11477
32. D. McMahon-Pratt Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection Infect. Immun. 61 1993 3351 3359
33. E. Mougneau Expression cloning of a protective Leishmania antigen Science 268 1995 563 566
34. S. Rafati Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase Clin. Exp. Immunol. 120 2000 134 138
35. V.S. Dole Immunization with recombinant LD1 antigens protects against experimental leishmaniasis Vaccine 19 2000 423 430
36. S. Stager Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis J. Immunol. 165 2000 7064 7071
37. M.E. Wilson A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice Infect. Immun. 63 1995 2062 2069
38. J.G. Valenzuela Toward a Defined Anti-Leishmania Vaccine Targeting Vector Antigens. Characterization of a protective salivary protein J. Exp. Med. 194 2001 331 342
39. J. Champsi, and D. McMahon-Pratt Membrane glycoprotein M-2 protects against Leishmania amazonensis infection Infect. Immun. 56 1988 3272 3279
40. E. Handman Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response Infect. Immun. 63 1995 4261 4267
41. N. Solioz The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis Vaccine 18 1999 850 859
42. Y.A. Skeiky LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile J. Immunol. 161 1998 6171 6179
43. J.R. Webb Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family Infect. Immun. 66 1998 3279 3289
44. T. Aebischer Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants Infect. Immun. 68 2000 1328 1336
45. L. Soong Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis Infect. Immun. 63 1995 3559 3566
46. D. Xu, and F.Y. Liew Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major Immunology 84 1995 173 176
47. S. Rafati A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major Vaccine 19 2001 3369 3375
48. L.C. Afonso The adjuvant effect of interleukin-12 in a vaccine against Leishmania major Science 263 1994 235 237
49. A. Campos-Neto Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease Infect. Immun. 69 2001 4103 4108
50. S. Gurunathan Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major J. Exp. Med. 186 1997 1137 1147
51. R.T. Kenney Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis J. Immunol. 163 1999 4481 4488
52. S. Mendez The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge J. Immunol. 166 2001 5122 5128
53. Dumonteil, E. et al. Fourth TDR/IDRI Meeting on Second-Generation Vaccines Against Leishmaniasis. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. TDR/PRD/Leish/Vac/01.1, 1-15. 2001. WHO/TDR
54. A. Ghosh Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections Vaccine 20 2001 59 66
55. D.H. Persing Taking toll: lipid A mimetics as adjuvants and immunomodulators Trends Microbiol. 10 2002 S32 S37
56. P. Kropf Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major Infect. Immun. 72 2004 1920 1928
57. N.A. Campos Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice Infect. Immun. 70 2002 2828 2836
58. P. Probst A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells Eur. J. Immunol. 27 1997 2634 2642
59. G.P. Walsh The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease Nat. Med. 2 1996 430 436
60. R.N. Coler Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis Infect. Immun. 70 2002 4215 4225
61. R. Badaro Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report Braz. J. Infect. Dis. 5 2001 223 232